Global Gene Therapy Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Gene Therapy market size will reach US$ 63520 million by 2031.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
The Gene Therapy market is driven by the growing demand for innovative treatments for rare genetic disorders, cancers, and chronic diseases that lack effective conventional therapies. Advancements in gene editing technologies such as CRISPR/Cas9, improved viral and non-viral delivery vectors, and increasing knowledge of the human genome have made gene therapy a promising option in precision medicine. Regulatory agencies are also offering accelerated approval pathways for breakthrough gene therapies, encouraging investment and speeding up clinical development. In addition, rising public and private funding, along with successful commercialization of landmark therapies like Zolgensma and Luxturna, are fueling confidence and expansion in this market.
Despite its potential, the Gene Therapy market faces several critical challenges, including high development and treatment costs, complex manufacturing processes, and safety concerns. Producing gene therapies requires highly specialized facilities and stringent quality control, leading to limited scalability and high prices, which can exceed millions of dollars per patient. Furthermore, long-term safety data are still lacking, with concerns over immune responses, off-target effects, and durability of treatment outcomes. Regulatory, ethical, and reimbursement hurdles also pose significant barriers to broader adoption. Addressing these challenges is essential to ensure accessibility, affordability, and the long-term success of gene therapy as a mainstream medical solution.
Global Gene Therapy key players include Biogen, Novartis, Gilead Sciences, etc. Global top three manufacturers hold a share about 75%. North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific, both have a share about 35 percent. In terms of product, Non-viral Gene Therapy is the largest segment, with a share about 55%. And in terms of application, the largest application is Neurological Diseases, followed by Cancer.
LPI (LP Information)' newest research report, the “Gene Therapy Industry Forecast” looks at past sales and reviews total world Gene Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Gene Therapy sales for 2025 through 2031. With Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Viral Gene Therapy
Non-Viral Gene Therapy
Segmentation by Application:
Neurological Diseases
Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Roche
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
CSL Behring
BioMarin Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
The Gene Therapy market is driven by the growing demand for innovative treatments for rare genetic disorders, cancers, and chronic diseases that lack effective conventional therapies. Advancements in gene editing technologies such as CRISPR/Cas9, improved viral and non-viral delivery vectors, and increasing knowledge of the human genome have made gene therapy a promising option in precision medicine. Regulatory agencies are also offering accelerated approval pathways for breakthrough gene therapies, encouraging investment and speeding up clinical development. In addition, rising public and private funding, along with successful commercialization of landmark therapies like Zolgensma and Luxturna, are fueling confidence and expansion in this market.
Despite its potential, the Gene Therapy market faces several critical challenges, including high development and treatment costs, complex manufacturing processes, and safety concerns. Producing gene therapies requires highly specialized facilities and stringent quality control, leading to limited scalability and high prices, which can exceed millions of dollars per patient. Furthermore, long-term safety data are still lacking, with concerns over immune responses, off-target effects, and durability of treatment outcomes. Regulatory, ethical, and reimbursement hurdles also pose significant barriers to broader adoption. Addressing these challenges is essential to ensure accessibility, affordability, and the long-term success of gene therapy as a mainstream medical solution.
Global Gene Therapy key players include Biogen, Novartis, Gilead Sciences, etc. Global top three manufacturers hold a share about 75%. North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific, both have a share about 35 percent. In terms of product, Non-viral Gene Therapy is the largest segment, with a share about 55%. And in terms of application, the largest application is Neurological Diseases, followed by Cancer.
LPI (LP Information)' newest research report, the “Gene Therapy Industry Forecast” looks at past sales and reviews total world Gene Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Gene Therapy sales for 2025 through 2031. With Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Viral Gene Therapy
Non-Viral Gene Therapy
Segmentation by Application:
Neurological Diseases
Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Roche
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
CSL Behring
BioMarin Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
124 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Gene Therapy Market Size by Player
- 4 Gene Therapy by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Gene Therapy Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
